JP Morgan Maintains Underweight on Moderna, Raises Price Target to $77

Benzinga Newsdesk www.benzinga.com Positive 81.2%

Neg 0% Neu 0% Pos 81.2%

JP Morgan analyst Jessica Fye maintains Moderna (NASDAQ:MRNA) with a Underweight and raises the price target from $40 to $77.